Sign In
Get Clay Free →

Suggestions

    Sergio Quezada

    CSO at Achilles Therapeutics and Professor of Cancer Immunology at UCL Cancer Institute

    Sergio Quezada is the Chief Scientific Officer at Achilles Therapeutics Limited, a position he has held since April 2020. He is also a co-founder of the company, which he established in June 2016. In addition to his role at Achilles, Quezada serves as a Professor of Cancer Immunology and Immunotherapy at the UCL Cancer Institute in London, where he has been involved in basic and translational research focused on immune regulation and cancer immunology since January 2011.

    His academic background includes a Bachelor of Science in Biochemistry and Molecular Biology from Pontificia Universidad Católica de Chile, completed between 1993 and 1999. He earned his PhD at Dartmouth College, where he studied immune regulation and transplantation tolerance from September 1999 to September 2004. Prior to his current roles, Quezada worked as a Research Associate at Memorial Sloan-Kettering Cancer Center from 2004 to 2010, specializing in cancer immunology and checkpoint blockade.1

    Related Questions

    What are Sergio Quezada's key achievements at Achilles Therapeutics Limited?
    How did Sergio Quezada transition from academia to industry?
    What are Sergio Quezada's main research interests in cancer immunology?
    What is the significance of Sergio Quezada's work on checkpoint blockade?
    How has Sergio Quezada's role as Chief Scientific Officer impacted Achilles Therapeutics?
    Sergio Quezada
    Sergio Quezada, photo 1
    Sergio Quezada, photo 2
    Add to my network

    Location

    Greater London, England, United Kingdom